Publicaciones en las que colabora con Marta Ruiz Ortega (11)

2023

  1. B- and T-lymphocyte attenuator could be a new player in accelerated atherosclerosis associated with chronic kidney disease

    Clinical science (London, England : 1979), Vol. 137, Núm. 17, pp. 1409-1429

  2. IMPROVE-PD Finder: A Web-Based Platform to Search and Share Peritoneal Dialysis Biobank, Registry, and Clinical Trial Metadata

    Kidney International Reports, Vol. 8, Núm. 4, pp. 912-915

2021

  1. Interleukin-17A: Potential mediator and therapeutic target in hypertension

    Nefrologia

  2. Interleuquina-17A: posible mediador y diana terapéutica en la hipertensión

    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, Vol. 41, Núm. 3, pp. 244-257

2020

  1. IL‐17A as a potential therapeutic target for patients on peritoneal dialysis

    Biomolecules, Vol. 10, Núm. 10, pp. 1-36

  2. Protective role of renal proximal tubular alpha-synuclein in the pathogenesis of kidney fibrosis

    Nature Communications, Vol. 11, Núm. 1

  3. TRAF3 Modulation: Novel Mechanism for the Anti-inflammatory Effects of the Vitamin D Receptor Agonist Paricalcitol in Renal Disease

    Journal of the American Society of Nephrology, Vol. 31, Núm. 9, pp. 2026-2042

2018

  1. Epigenetic modification mechanisms involved in inflammation and fibrosis in renal pathology

    Mediators of Inflammation, Vol. 2018

  2. Role of epidermal growth factor receptor (EGFR) and its ligands in kidney inflammation and damage

    Mediators of Inflammation, Vol. 2018

2015

  1. Paricalcitol inhibits aldosterone-induced proinflammatory factors by modulating epidermal growth factor receptor pathway in cultured tubular epithelial cells

    BioMed Research International, Vol. 2015

2011

  1. Globotriaosylsphingosine actions on human glomerular podocytes: Implications for Fabry nephropathy

    Nephrology Dialysis Transplantation, Vol. 26, Núm. 6, pp. 1797-1802